{"hands_on_practices": [{"introduction": "The modern diagnosis of primary membranous nephropathy has been revolutionized by the discovery of specific autoantibodies. This first exercise allows you to practice the quantitative reasoning that underpins the use of these powerful serologic tools. By applying Bayes' theorem, you will calculate how a positive anti–phospholipase A$2$ receptor (anti-PLA$2$R) antibody test dramatically increases the certainty of a diagnosis, a key skill in evidence-based clinical decision-making [@problem_id:4870505].", "problem": "A patient aged $45$ years presents with nephrotic-range proteinuria and no clinical or serologic evidence of secondary causes. Based on epidemiology, clinical features, and preliminary work-up, your multidisciplinary team estimates a pretest probability of primary membranous nephropathy of $0.60$. You order an anti–phospholipase A$2$ receptor (anti-PLA$2$R) immunoassay. In your laboratory, at the chosen diagnostic threshold, the assay’s sensitivity for primary membranous nephropathy is $0.78$ and its specificity against alternative diagnoses is $0.98$. Assume these test characteristics are well calibrated for your patient population and that the test result is conditionally independent given disease status.\n\nFor a positive anti-PLA$2$R test result, compute the post-test probability that the patient has primary membranous nephropathy using only established definitions of sensitivity and specificity together with the rules of conditional probability. Express your final answer as a decimal fraction and round to $4$ significant figures.", "solution": "The user-provided problem is assessed to be valid. It is scientifically grounded in the principles of medical diagnostics and probability theory, self-contained, and well-posed. The provided data are consistent and sufficient for a unique solution.\n\nThe problem requires the calculation of the post-test probability of a patient having primary membranous nephropathy given a positive test result. This is a classic application of Bayes' theorem.\n\nLet us define the following events:\n- $D$: The patient has primary membranous nephropathy.\n- $D^c$: The patient does not have primary membranous nephropathy (i.e., has an alternative diagnosis).\n- $T^+$: The anti-PLA$2$R test result is positive.\n- $T^-$: The anti-PLA$2$R test result is negative.\n\nFrom the problem statement, we are given the following probabilities:\n1.  The pre-test probability (or prior probability) of the patient having the disease is $P(D) = 0.60$.\n2.  The sensitivity of the test, which is the probability of a positive test result given that the patient has the disease, is $P(T^+|D) = 0.78$.\n3.  The specificity of the test, which is the probability of a negative test result given that the patient does not have the disease, is $P(T^-|D^c) = 0.98$.\n\nThe objective is to compute the post-test probability (or posterior probability) of the patient having the disease given a positive test result, which is denoted by $P(D|T^+)$.\n\nAccording to Bayes' theorem, the posterior probability $P(D|T^+)$ is given by the formula:\n$$P(D|T^+) = \\frac{P(T^+|D) P(D)}{P(T^+)}$$\nTo use this formula, we first need to calculate the denominator, $P(T^+)$, which is the overall probability of obtaining a positive test result. This is the marginal probability of $T^+$ and can be calculated using the law of total probability:\n$$P(T^+) = P(T^+|D)P(D) + P(T^+|D^c)P(D^c)$$\n\nWe have most of the components for this calculation from the givens. The missing components are $P(D^c)$ and $P(T^+|D^c)$. These can be derived as follows:\n- The probability of not having the disease is the complement of having the disease:\n$$P(D^c) = 1 - P(D) = 1 - 0.60 = 0.40$$\n- The probability of a positive test in a patient without the disease, $P(T^+|D^c)$, is the complement of the specificity. The specificity, $P(T^-|D^c)$, is the probability of a negative test in a non-diseased patient. Therefore:\n$$P(T^+|D^c) = 1 - P(T^-|D^c) = 1 - 0.98 = 0.02$$\nThis value, $P(T^+|D^c)$, is also known as the false positive rate.\n\nNow, we can substitute these values into the formula for the total probability of a positive test, $P(T^+)$:\n$$P(T^+) = (0.78)(0.60) + (0.02)(0.40)$$\n$$P(T^+) = 0.468 + 0.008$$\n$$P(T^+) = 0.476$$\n\nWith $P(T^+)$ calculated, we can now compute the post-test probability $P(D|T^+)$ using Bayes' theorem:\n$$P(D|T^+) = \\frac{P(T^+|D) P(D)}{P(T^+)}$$\nThe numerator represents the probability of having the disease AND getting a positive test result (a true positive):\n$$P(T^+ \\cap D) = P(T^+|D) P(D) = (0.78)(0.60) = 0.468$$\nSubstituting the numerator and the denominator into Bayes' theorem:\n$$P(D|T^+) = \\frac{0.468}{0.476}$$\n$$P(D|T^+) \\approx 0.983193277...$$\n\nThe problem requires the final answer to be expressed as a decimal fraction rounded to $4$ significant figures. Rounding the calculated value gives:\n$$P(D|T^+) \\approx 0.9832$$\nThis is the posterior probability that the patient has primary membranous nephropathy given the positive test result.", "answer": "$$\n\\boxed{0.9832}\n$$", "id": "4870505"}, {"introduction": "Accurate diagnosis requires not only recognizing a disease but also confidently distinguishing it from its mimics. This clinical case challenges you to synthesize a complete dataset—from patient history to detailed kidney biopsy findings—to differentiate membranous nephropathy from infection-related glomerulonephritis. This practice is crucial for honing your differential diagnosis skills and understanding why correct identification of the underlying pathology is essential for choosing the right treatment and avoiding potentially harmful therapies [@problem_id:4870447].", "problem": "A $62$-year-old man with type $2$ diabetes mellitus was treated for methicillin-sensitive Staphylococcus aureus cellulitis $2$ weeks ago. He presents with new-onset edema, blood pressure of $152/94$ mm Hg, and urine dipstick showing $4+$ protein with microscopic hematuria. The urine protein-to-creatinine ratio is $6.2$ g/g, serum creatinine is $2.1$ mg/dL (baseline $1.0$ mg/dL), and serum albumin is $2.4$ g/dL. Complement testing reveals low complement component $3$ (C$3$) at $62$ mg/dL (reference $90$–$180$ mg/dL) with normal complement component $4$ (C$4$). Serologic testing shows negative M-type phospholipase A$2$ receptor (PLA$2$R) antibodies and negative thrombospondin type-$1$ domain–containing $7$A (THSD$7$A) antibodies.\n\nKidney biopsy demonstrates the following:\n- Light microscopy: diffuse endocapillary hypercellularity with numerous neutrophils and occasional double-contoured glomerular basement membranes; no well-formed “spikes” are identified on silver stain.\n- Immunofluorescence (IF): granular capillary loop deposits with dominant immunoglobulin A (IgA) ($3+$) and complement component $3$ (C$3$) ($3+$), with weaker immunoglobulin G (IgG) ($1$–$2+$); kappa and lambda light chains are polytypic.\n- Electron microscopy: large, coarse, irregular subepithelial “hump”-shaped deposits and mesangial deposits; the subepithelial deposits are not uniform or organized along the glomerular basement membrane.\n\nStarting from first principles of immune complex–mediated glomerular injury, deposition location, complement pathway activation, and autoantigen specificity, which option best explains why membranous nephropathy is unlikely in this patient and identifies the most appropriate immediate management?\n\nA. Initiate rituximab for presumed primary membranous nephropathy, because granular IgG along capillary loops is pathognomonic for membranous nephropathy.\n\nB. Membranous nephropathy is unlikely because IF shows dominant IgA with low serum C$3$ and electron microscopy reveals subepithelial “hump” deposits indicative of infection-related glomerulonephritis; urgently treat the staphylococcal source and provide supportive care, avoiding immunosuppression.\n\nC. Membranous nephropathy is unlikely solely because anti-PLA$2$R antibodies are negative; proceed with a cyclophosphamide–glucocorticoid regimen to reduce proteinuria.\n\nD. Membranous nephropathy remains likely because proteinuria exceeds $3.5$ g/day and serum albumin is below $3.0$ g/dL; manage conservatively with renin–angiotensin–aldosterone system (RAAS) blockade and observation.\n\nE. Membranous nephropathy is excluded by absence of IgG subclass $4$; the pattern represents membranous-like IgA nephropathy, warranting high-dose glucocorticoids.", "solution": "### Derivation from First Principles\n\nThe patient presents with an acute kidney injury (creatinine rise from $1.0$ mg/dL to $2.1$ mg/dL) and a mixed nephritic-nephrotic syndrome. The nephrotic components are heavy proteinuria (urine protein-to-creatinine ratio of $6.2$ g/g) and hypoalbuminemia (serum albumin of $2.4$ g/dL). The nephritic components are hypertension ($152/94$ mm Hg), acute kidney injury, and microscopic hematuria. This clinical picture developed $2$ weeks after treatment for a methicillin-sensitive *Staphylococcus aureus* (MSSA) skin infection. This temporal relationship is highly suggestive of an infection-related glomerulonephritis (IRGN).\n\nWe must analyze the provided data in the context of immune complex-mediated glomerular disease, comparing the expected findings for membranous nephropathy (MN) versus IRGN.\n\n1.  **Autoantigen Specificity and Serology:**\n    *   **Primary MN:** This is an autoimmune disease where autoantibodies target podocyte antigens, most commonly PLA$2$R or THSD$7$A. The provided serologic tests for anti-PLA$2$R and anti-THSD$7$A are negative. While a minority of primary MN cases can be seronegative, this negative result, in conjunction with other findings, weighs against the diagnosis.\n    *   **IRGN:** This disease is driven by an immune response to an exogenous antigen (in this case, from *S. aureus*). Immune complexes are formed from bacterial antigens and host antibodies, which then deposit in the glomeruli.\n\n2.  **Complement Pathway Activation:**\n    *   The finding of a low serum C$3$ level ($62$ mg/dL) with a normal C$4$ level is a classic sign of **alternative complement pathway activation**. Bacterial cell wall components are potent activators of this pathway.\n    *   In contrast, primary MN typically does not consume complement systemically, so C$3$ and C$4$ levels are usually normal. The isolated low C$3$ is a strong argument against primary MN and for IRGN.\n\n3.  **Kidney Biopsy Analysis:**\n    *   **Light Microscopy (LM):** The presence of `diffuse endocapillary hypercellularity with numerous neutrophils` is a hallmark of a proliferative and exudative glomerulonephritis, typical of IRGN. Primary MN is characteristically a non-proliferative disease. The absence of `“spikes”` on silver stain further argues against established MN.\n    *   **Immunofluorescence (IF):** Typical primary MN is defined by dominant granular capillary loop staining for IgG (specifically IgG4) and C3. This patient's biopsy shows dominant IgA ($3+$) and C3 ($3+$), with weaker IgG staining. This \"IgA-dominant\" pattern is a well-recognized variant of IRGN, particularly in the setting of staphylococcal infections, and is fundamentally different from the IF pattern of primary MN.\n    *   **Electron Microscopy (EM):** The finding of `large, coarse, irregular subepithelial “hump”-shaped deposits` is pathognomonic for post-infectious glomerulonephritis. These are morphologically distinct from the more uniform, organized subepithelial deposits that characterize MN.\n\n**Conclusion:** The combination of a recent staphylococcal infection, a nephritic-nephrotic presentation, alternative pathway complement activation, and pathognomonic biopsy findings (endocapillary hypercellularity, IgA/C3 dominance, and subepithelial \"humps\") establishes the diagnosis as IgA-dominant Infection-Related Glomerulonephritis. This makes primary membranous nephropathy extremely unlikely.\n\n**Management:** The fundamental principle for treating IRGN is eradication of the inciting infection. The second component of management is supportive care (control of blood pressure, management of edema). Immunosuppressive therapy is not indicated and is potentially harmful.\n\n### Evaluation of Options\n\n*   **A. Initiate rituximab for presumed primary membranous nephropathy...** This is incorrect. The diagnosis is not primary MN, and rituximab is contraindicated.\n*   **B. Membranous nephropathy is unlikely because IF shows dominant IgA with low serum C$3$ and electron microscopy reveals subepithelial “hump” deposits indicative of infection-related glomerulonephritis; urgently treat the staphylococcal source and provide supportive care, avoiding immunosuppression.** This option accurately identifies the key features ruling out MN and confirming IRGN and outlines the correct management strategy.\n*   **C. Membranous nephropathy is unlikely solely because anti-PLA$2$R antibodies are negative...** This is an insufficient reason. The biopsy is far more definitive. The proposed treatment (cyclophosphamide) is incorrect and dangerous.\n*   **D. Membranous nephropathy remains likely because proteinuria exceeds $3.5$ g/day...** This incorrectly equates nephrotic syndrome with a diagnosis of MN, ignoring all contradictory evidence. It also omits the most critical management step of treating the infection.\n*   **E. Membranous nephropathy is excluded by absence of IgG subclass $4$; the pattern represents membranous-like IgA nephropathy...** This option makes an unsubstantiated claim (IgG4 absence), uses an incorrect diagnostic term, and recommends an incorrect treatment.\n\nTherefore, option B is the only one that correctly synthesizes the data and proposes an evidence-based plan.", "answer": "$$\\boxed{B}$$", "id": "4870447"}, {"introduction": "After confirming a diagnosis of primary membranous nephropathy, the next critical step is to assess the patient's risk of progression and formulate a state-of-the-art treatment plan. This advanced problem presents a case with high-risk features, including secondary pathological changes, requiring you to integrate all available clinical, serological, and biopsy data. This exercise [@problem_id:4870465] will guide you through designing a comprehensive, modern management strategy that incorporates risk stratification, targeted immunotherapy, and novel renoprotective agents, reflecting the current standard of care for patients with severe disease.", "problem": "A $48$-year-old man presents with $3$ months of progressive lower-extremity edema, frothy urine, and fatigue. Urinalysis shows heavy proteinuria; a $24$-hour collection confirms $9.2$ g/day of protein excretion. Serum albumin is $1.8$ g/dL, low-density lipoprotein cholesterol is $160$ mg/dL, and estimated glomerular filtration rate (eGFR) is $68$ mL/min per $1.73$ m$^2$. Anti–phospholipase A$2$ receptor (anti-PLA2R) antibody is positive at $120$ RU/mL, thrombospondin type-$1$ domain-containing $7$A (THSD7A) antibody is negative, antinuclear antibody is negative, anti–double-stranded deoxyribonucleic acid is negative, complement levels are normal, and hepatitis B and C serologies are negative. Age-appropriate malignancy screening is unrevealing. \n\nKidney biopsy shows the following. Light microscopy reveals $20$ glomeruli with diffuse thickening of glomerular capillary walls, glomerular basement membrane (GBM) “spikes” on Jones silver stain, minimal mesangial and endocapillary proliferation, and segmental sclerosis in $3$ of $20$ glomeruli, largely perihilar. Immunofluorescence (IF) demonstrates granular immunoglobulin G (IgG) and complement component $3$ (C$3$) along the GBM, with immunoglobulin G subclass $4$ (IgG$4$) predominance; complement component $1$q (C$1$q), immunoglobulin A (IgA), and immunoglobulin M (IgM) are negative. Electron microscopy (EM) shows multiple subepithelial electron-dense deposits and diffuse foot process effacement $80\\%$ without mesangial or subendothelial deposits.\n\nUsing fundamental definitions of glomerular disease pathobiology and well-tested clinicopathologic correlations, decide which option best justifies the diagnosis and outlines a modern, evidence-based treatment plan that accounts for the segmental sclerosis. Choose the single best answer.\n\nA. Primary membranous nephropathy with secondary adaptive focal segmental glomerulosclerosis (FSGS) lesions from podocyte injury and hyperfiltration; initiate renin-angiotensin-aldosterone system (RAAS) blockade and sodium-glucose cotransporter $2$ (SGLT$2$) inhibition, risk-stratify by persistent proteinuria and anti-PLA2R titer, and start rituximab immunotherapy given sustained nephrotic-range proteinuria and high anti-PLA2R, with close monitoring of anti-PLA2R titers and consideration of venous thromboembolism (VTE) prophylaxis at serum albumin $2.0$ g/dL.\n\nB. Primary FSGS; the presence of segmental sclerosis establishes the primary diagnosis despite GBM spikes, so high-dose glucocorticoids for $16$ weeks should be started, and anti-PLA2R testing is not relevant to management.\n\nC. Class V lupus membranous nephritis; GBM spikes and granular IF are diagnostic, so treat with mycophenolate mofetil and hydroxychloroquine along with angiotensin-converting enzyme inhibition, regardless of antinuclear antibody and complement results.\n\nD. Minimal change disease with secondary sclerosis; segmental sclerosis indicates evolution from minimal change disease, so treat with prednisone monotherapy and defer immunologic testing and anti-PLA2R measurements.\n\nE. Secondary membranous nephropathy due to occult hepatitis B; immunosuppression should be avoided and antiviral therapy (e.g., entecavir) initiated despite negative serologies, because GBM spikes are typical of infection-associated membranous disease.", "solution": "The problem statement is subjected to validation.\n\n**Step 1: Extract Givens**\n- **Patient Profile**: A $48$-year-old man.\n- **Clinical Presentation**: $3$ months of progressive lower-extremity edema, frothy urine, and fatigue.\n- **Laboratory Data**:\n    - Urinalysis: Heavy proteinuria.\n    - $24$-hour urine protein: $9.2$ g/day.\n    - Serum albumin: $1.8$ g/dL.\n    - Low-density lipoprotein (LDL) cholesterol: $160$ mg/dL.\n    - Estimated glomerular filtration rate (eGFR): $68$ mL/min per $1.73$ m$^2$.\n    - Anti–phospholipase A$2$ receptor (anti-PLA2R) antibody: Positive at $120$ RU/mL.\n    - Thrombospondin type-$1$ domain-containing $7$A (THSD7A) antibody: Negative.\n    - Antinuclear antibody (ANA): Negative.\n    - Anti–double-stranded deoxyribonucleic acid (anti-dsDNA): Negative.\n    - Complement levels: Normal.\n    - Hepatitis B and C serologies: Negative.\n- **Malignancy Screening**: Age-appropriate and unrevealing.\n- **Kidney Biopsy Data**:\n    - **Light Microscopy (LM)**: On a sample of $20$ glomeruli, findings include diffuse thickening of glomerular capillary walls, glomerular basement membrane (GBM) “spikes” on Jones silver stain, minimal mesangial and endocapillary proliferation, and segmental sclerosis in $3$ of $20$ glomeruli, with a largely perihilar distribution.\n    - **Immunofluorescence (IF)**: Granular immunoglobulin G (IgG) and complement component $3$ (C$3$) along the GBM, with immunoglobulin G subclass $4$ (IgG$4$) predominance. Complement component $1$q (C$1$q), immunoglobulin A (IgA), and immunoglobulin M (IgM) are negative.\n    - **Electron Microscopy (EM)**: Multiple subepithelial electron-dense deposits and diffuse foot process effacement $80\\%$. No mesangial or subendothelial deposits were observed.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Grounding**: The problem describes a classic case of nephrotic syndrome. The clinical signs (edema, frothy urine), laboratory values (severe proteinuria, hypoalbuminemia, hyperlipidemia), and serological workup are coherent and standard in nephrology. The detailed kidney biopsy findings (LM, IF, EM) are internally consistent and pathognomonic for a specific glomerular disease. The association of anti-PLA2R antibodies with membranous nephropathy is a well-established scientific fact. The problem is firmly scientifically grounded.\n- **Well-Posedness**: The problem provides a rich dataset from clinical, laboratory, and pathological evaluations. The question asks for a diagnosis and management plan, for which a single best answer can be determined by applying current, evidence-based medical guidelines. The co-existence of membranous features and segmental sclerosis is a recognized, albeit complex, clinical scenario that has a standard interpretation, making the problem challenging but well-posed.\n- **Objectivity**: The problem is presented using objective, clinical language, and quantitative data. There are no subjective or value-based statements.\n\n**Step 3: Verdict and Action**\nThe problem statement is valid. It is scientifically sound, well-posed, and objective, presenting a realistic and solvable clinical vignette. The solution process will now proceed.\n\n**Derivation of the Solution**\n\n1.  **Diagnosis Synthesis**: The patient presents with nephrotic syndrome, characterized by proteinuria ($9.2$ g/day), hypoalbuminemia ($1.8$ g/dL), and edema. The central task is to identify the underlying cause.\n    - The kidney biopsy provides definitive evidence. On light microscopy, diffuse GBM thickening with \"spikes\" is characteristic of membranous nephropathy (MN). On immunofluorescence, granular deposition of IgG and C$3$ along the capillary walls confirms an immune complex-mediated process. Electron microscopy showing subepithelial deposits is the pathognomonic ultrastructural feature of MN.\n    - The specific etiology of MN (primary vs. secondary) is clarified by serology and further biopsy details. The positive anti-PLA2R antibody test at a high titer ($120$ RU/mL) has very high specificity for primary membranous nephropathy (pMN). This is strongly supported by the IgG$4$ predominance on IF, which is typical of pMN. The comprehensive negative workup for secondary causes (malignancy, lupus, infections like hepatitis B/C) further solidifies the diagnosis of pMN.\n    - The finding of segmental sclerosis in $3$ of $20$ glomeruli must be properly contextualized. Given the overwhelming evidence for pMN, the sclerosis is not the primary disease. Instead, it represents secondary focal segmental glomerulosclerosis (FSGS). This is an adaptive or maladaptive response to the severe podocyte injury and nephron loss caused by the primary membranous process. The severe proteinuria leads to compensatory hyperfiltration in the remaining healthier glomeruli, which puts excessive strain on them, leading to further injury and eventual scarring (sclerosis). The perihilar location of the sclerosis is also typical for this \"hyperfiltration\" type of secondary FSGS. Thus, the complete diagnosis is **primary membranous nephropathy with secondary adaptive FSGS**.\n\n2.  **Management Strategy**: Management for this patient should be aggressive due to multiple high-risk features for progression to end-stage kidney disease.\n    - **Risk Stratification**: The patient is at high risk based on the 2021 KDIGO guidelines. High-risk features include severe, persistent nephrotic syndrome (proteinuria $8$ g/day, albumin $2.5$ g/dL), a high anti-PLA2R antibody titer ($50$ RU/mL), and a declining eGFR (though $68$ mL/min per $1.73$ m$^2$ is currently only mildly reduced, it is a risk factor). The presence of secondary FSGS also indicates a more advanced and severe disease process.\n    - **Supportive Care**: This is fundamental for all patients with proteinuric kidney disease. It includes:\n        - **Renin-angiotensin-aldosterone system (RAAS) blockade** with an ACE inhibitor or an ARB to reduce proteinuria and control blood pressure.\n        - **Sodium-glucose cotransporter $2$ (SGLT$2$) inhibition**. Recent landmark trials have established the benefit of SGLT$2$ inhibitors in slowing the progression of chronic kidney disease, including non-diabetic proteinuric diseases like MN. This is a key component of modern therapy.\n        - **Venous thromboembolism (VTE) prophylaxis**: Nephrotic syndrome is a hypercoagulable state. With a serum albumin of $1.8$ g/dL (generally, the threshold is $2.0-2.5$ g/dL), the risk of VTE is very high, and prophylactic anticoagulation should be strongly considered or initiated.\n        - Management of edema and hyperlipidemia.\n    - **Immunosuppressive Therapy**: Given the high-risk profile, immediate immunosuppression is warranted without a prolonged trial of supportive care alone.\n        - **Rituximab**, a monoclonal antibody against the B-cell antigen CD$20$, is now recommended as a first-line agent for pMN. It targets the production of pathogenic autoantibodies like anti-PLA2R. Its efficacy is comparable to older cytotoxic regimens (cyclophosphamide/steroids) but with a more favorable safety profile.\n        - **Monitoring**: The response to therapy should be monitored by tracking the reduction in proteinuria and the decline in anti-PLA2R antibody titers. Immunological remission (fall in antibody titer) typically precedes clinical remission (reduction in proteinuria).\n\n**Option-by-Option Analysis**\n\n*   **A. Primary membranous nephropathy with secondary adaptive focal segmental glomerulosclerosis (FSGS) lesions from podocyte injury and hyperfiltration; initiate renin-angiotensin-aldosterone system (RAAS) blockade and sodium-glucose cotransporter $2$ (SGLT$2$) inhibition, risk-stratify by persistent proteinuria and anti-PLA2R titer, and start rituximab immunotherapy given sustained nephrotic-range proteinuria and high anti-PLA2R, with close monitoring of anti-PLA2R titers and consideration of venous thromboembolism (VTE) prophylaxis at serum albumin $2.0$ g/dL.**\n    - This option correctly identifies primary MN as the diagnosis and correctly interprets the FSGS lesions as secondary. It outlines a modern, comprehensive, and evidence-based management plan, including supportive care with RAAS blockade and SGLT$2$ inhibition, appropriate risk stratification, first-line immunotherapy with rituximab for a high-risk patient, proper monitoring, and consideration of VTE prophylaxis. This aligns perfectly with the derived solution.\n    - **Verdict: Correct.**\n\n*   **B. Primary FSGS; the presence of segmental sclerosis establishes the primary diagnosis despite GBM spikes, so high-dose glucocorticoids for $16$ weeks should be started, and anti-PLA2R testing is not relevant to management.**\n    - This option makes a fundamental diagnostic error by prioritizing the secondary sclerosis over the pathognomonic features of MN. It incorrectly dismisses the significance of the GBM spikes and the highly specific positive anti-PLA2R antibody test. The proposed treatment is for primary FSGS, which is the wrong diagnosis.\n    - **Verdict: Incorrect.**\n\n*   **C. Class V lupus membranous nephritis; GBM spikes and granular IF are diagnostic, so treat with mycophenolate mofetil and hydroxychloroquine along with angiotensin-converting enzyme inhibition, regardless of antinuclear antibody and complement results.**\n    - This option incorrectly diagnoses lupus nephritis. It critically errs by advising to ignore the negative ANA, negative anti-dsDNA, and normal complement levels, which are key data points that argue against systemic lupus erythematosus. The IF pattern (IgG$4$ dominant, no \"full house\") and positive anti-PLA2R also strongly favor primary MN over lupus.\n    - **Verdict: Incorrect.**\n\n*   **D. Minimal change disease with secondary sclerosis; segmental sclerosis indicates evolution from minimal change disease, so treat with prednisone monotherapy and defer immunologic testing and anti-PLA2R measurements.**\n    - This option incorrectly diagnoses minimal change disease (MCD). The biopsy findings of diffuse GBM thickening, spikes, and prominent immune deposits on IF/EM definitively rule out MCD, which is defined by normal LM and negative IF.\n    - **Verdict: Incorrect.**\n\n*   **E. Secondary membranous nephropathy due to occult hepatitis B; immunosuppression should be avoided and antiviral therapy (e.g., entecavir) initiated despite negative serologies, because GBM spikes are typical of infection-associated membranous disease.**\n    - This option makes an unsubstantiated diagnosis of hepatitis B-associated MN in the face of negative serologies. It is not standard practice to treat for an infection without evidence. Further, the positive anti-PLA2R antibody and IgG$4$ predominance strongly point away from a secondary cause like hepatitis B and toward a primary autoimmune etiology. The proposed management is inappropriate and potentially harmful.\n    - **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "4870465"}]}